Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(03): 126-129
DOI: 10.1055/s-0041-1723078
Original Article: Brain Tumor

Frequency and Prognosis of Epidermal Growth Factor Receptor Variant III Mutations in Glioblastoma Multiforme among Indian Patients: A Single-Institution Study

Wesley Mannirathil Jose
1   Department of Medical Oncology and Hematology, Cancer Institute, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Vinayak Munirathnam
1   Department of Medical Oncology and Hematology, Cancer Institute, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
V. Narendranath
2   Department of Molecular Medicine, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Arun Philip
1   Department of Medical Oncology and Hematology, Cancer Institute, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Pavithran Keechilat
1   Department of Medical Oncology and Hematology, Cancer Institute, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
› Author Affiliations Financial Support and Sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background Glioblastoma multiforme (GBM) is a disease with poor outcome. Alterations or mutations in epidermal growth factor receptors (EGFRs) are found in GBM and may be targeted to improve outcomes.

Aims We analyzed the frequency of EGFR variant III (vIII) mutations in patients with GBM and their outcomes after standard treatment.

Materials and Methods This is a retrospective study conducted in a single tertiary cancer center in south India. Forty patients with GBM who had their entire treatment done at this center were identified, and their primary tumor tissue blocks were retrieved. Genomic DNA was extracted, and molecular analysis was performed and analyzed. The results of mutational analysis were correlated with treatment outcome of the patients.

Statistical Analysis Survival outcome was analyzed using the Kaplan–Meier method. The log-rank test was used to assess the association between the groups and various parameters.

Results Our study showed a similar incidence of EGFR vIII alterations as published in world literature, but we did not find any difference in overall survival (OS) and progression-free survival (PFS) in patients with EGFR vIII mutation compared with nonmutant cohort.

Conclusions Contrary to the existing literature which indicated EGFR vIII alterations to be a negative prognostic indicator, our study did not find it to be an independent predictor of prognosis among Indian GBM patients treated with present standard of care.

Keywords

epidermal growth factor receptor - glioblastoma multiforme - mutation - variant III


Publication History

Article published online:
26 April 2021

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Louis DN, Perry A, Reifenberger G. et al. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131 (06) 803-820
    CrossrefPubMedGoogle Scholar
  • 2 Ostrom QT, Gittleman H, de Blank PM. et al. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the united states in 2008-2012. Neuro-oncol 2016; 18 (Suppl. 01) i1-i50
    CrossrefPubMedGoogle Scholar
  • 3 Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol 2008; 87 (01) 111-114
    CrossrefPubMedGoogle Scholar
  • 4 Ostrom QT, Bauchet L, Davis FG. et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncol 2014; 16 (07) 896-913
    CrossrefPubMedGoogle Scholar
  • 5 Ohgaki H, Dessen P, Jourde B. et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64 (19) 6892-6899
    CrossrefPubMedGoogle Scholar
  • 6 von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995; 15 (03) 328-338
    CrossrefPubMedGoogle Scholar
  • 7 Aldape KD, Ballman K, Furth A. et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004; 63 (07) 700-707
    CrossrefPubMedGoogle Scholar
  • 8 Liu L, Bäcklund LM, Nilsson BR. et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) 2005; 83 (11) 917-926
    CrossrefPubMedGoogle Scholar
  • 9 Nozawa T, Okada M, Natsumeda M. et al. EGFRvIII is expressed in cellular areas of tumor in a subset of glioblastoma. Neurol Med Chir (Tokyo) 2019; 59 (03) 89-97
    CrossrefPubMedGoogle Scholar
  • 10 Keller S, Schmidt MHH. EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: Combination therapies for an effective treatment. Int J Mol Sci 2017; 18 (06) e1295
    CrossrefPubMedGoogle Scholar
  • 11 Shinojima N, Tada K, Shiraishi S. et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63 (20) 6962-6970
    PubMedGoogle Scholar
  • 12 Heimberger AB, Hlatky R, Suki D. et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11 (04) 1462-1466
    CrossrefPubMedGoogle Scholar
  • 13 Umesh S, Tandon A, Santosh V. et al. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol 2009; 28 (05) 362-372
    PubMedGoogle Scholar
  • 14 Xavier S, Gopi Mohan C, Nair S, Menon KN, Vijayachandran LS. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation. Int J Biol Macromol 2019; 124: 17-24
    CrossrefPubMedGoogle Scholar
  • 15 Jiang H, Gao H, Kong J. et al. Selective targeting of glioblastoma with EGFRvIII/EGFR bitargeted chimeric antigen receptor T cell. Cancer Immunol Res 2018; 6 (11) 1314-1326
    CrossrefPubMedGoogle Scholar